Cargando…

Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

PURPOSES: In this study, we aimed to verify plasma fibroblast growth factor 21 (FGF21) elevation in newly diagnosed overweight patients with type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD) and to evaluate the effectiveness of liraglutide on reducing liver fat content and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Xinyue, Wu, Xiaojuan, Jia, Yumei, Fu, Jing, Zhang, Lin, Jiang, Tao, Liu, Jia, Wang, Guang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519721/ https://www.ncbi.nlm.nih.gov/pubmed/34660809 http://dx.doi.org/10.1155/2021/3715026

Ejemplares similares

Longitudinal changes in serum adropin levels and liver fat content during liraglutide treatment in newly diagnosed patients with type 2 diabetes mellitus and metabolic dysfunction-associated fatty liver disease
por: Zhang, Lin, et al.
Publicado: (2023)

Risk Factors for Nonalcoholic Fatty Liver Disease with Different Insulin Resistance in a Nonobese Chinese Population
por: Wu, Xiaojuan, et al.
Publicado: (2022)

Liraglutide with Lifestyle Intervention in Adolescents with Overweight/Obesity, Nonalcoholic Fatty Liver Disease, and Type II Diabetes Mellitus
por: Kohut, Taisa, et al.
Publicado: (2021)

Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients with Newly Diagnosed Type 2 Diabetes
por: Liu, Jia, et al.
Publicado: (2017)

Liraglutide Attenuates Nonalcoholic Fatty Liver Disease by Modulating Gut Microbiota in Rats Administered a High-Fat Diet
por: Zhang, Ningjing, et al.
Publicado: (2020)

Fibroblast Growth Factor 21 is Related to Atherosclerosis Independent of Nonalcoholic Fatty Liver Disease and Predicts Atherosclerotic Cardiovascular Events
por: Wu, Liang, et al.
Publicado: (2020)

Acute exercise does not decrease liver fat in men with overweight or NAFLD
por: Bilet, L., et al.
Publicado: (2015)

Dietary Composition and Its Association with Newly Diagnosed Nonalcoholic Fatty Liver Disease and Insulin Resistance
por: Charatcharoenwitthaya, Phunchai, et al.
Publicado: (2021)

Complementary Role of Fibroblast Growth Factor 21 and Cytokeratin 18 in Monitoring the Different Stages of Nonalcoholic Fatty Liver Disease
por: Wu, Guangyu, et al.
Publicado: (2017)

Fibroblast Growth Factor-21 as a Potential Therapeutic Target of Nonalcoholic Fatty Liver Disease
por: Raptis, Dimitrios D, et al.
Publicado: (2023)

Effects of Liraglutide on Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
por: Song, Tiantian, et al.
Publicado: (2021)

Liraglutide ameliorates nonalcoholic fatty liver disease in diabetic mice via the IRS2/PI3K/Akt signaling pathway
por: Yang, Pijian, et al.
Publicado: (2019)

The association of pericardial fat and peri-aortic fat with severity of nonalcoholic fatty liver disease
por: Lee, Chun-Wei, et al.
Publicado: (2022)

Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease
por: Alisi, Anna, et al.
Publicado: (2013)

Association between Intrapancreatic Fat Deposition and Lower High-Density Lipoprotein Cholesterol in Individuals with Newly Diagnosed T2DM
por: Wang, Jianliang, et al.
Publicado: (2023)

The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone
por: Ohki, Takamasa, et al.
Publicado: (2012)

Estimation of Liver Fat by FibroScan in Patients With Nonalcoholic Fatty Liver Disease
por: Shrestha, Rupesh, et al.
Publicado: (2021)

Untreated newly diagnosed essential hypertension is associated with nonalcoholic fatty liver disease in a population of a hypertensive center
por: Michopoulos, Spyros, et al.
Publicado: (2016)

Relationship between grip strength and newly diagnosed nonalcoholic fatty liver disease in a large-scale adult population
por: Meng, Ge, et al.
Publicado: (2016)

Major Dietary Patterns in Association with the Grades of Nonalcoholic Fatty Liver Disease in Newly Diagnosed Patients Living in North of Iran
por: Mansour-Ghanaei, Fariborz, et al.
Publicado: (2022)

Nonalcoholic Fatty Liver Disease (NAFLD), But not Its Susceptibility Gene Variants, Influences the Decrease of Kidney Function in Overweight/Obese Children
por: Di Costanzo, Alessia, et al.
Publicado: (2019)

The effects of liraglutide on liver enzymes and metabolic factors in patients with nonalcoholic steatohepatitis: a meta-analysis of randomized controlled trials
por: Malik, Adnan, et al.
Publicado: (2022)

Sex-specific Cutoff Values of Visceral Fat Area for Lean vs. Overweight/Obese Nonalcoholic Fatty Liver Disease in Asians
por: Lee, Sunyoung, et al.
Publicado: (2022)

Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver
por: Dongiovanni, P., et al.
Publicado: (2017)

Noninvasive Quantitative Detection Methods of Liver Fat Content in Nonalcoholic Fatty Liver Disease
por: Lv, Shujing, et al.
Publicado: (2018)

The Impact of Nonalcoholic Fatty Liver Disease on Renal Function in Children with Overweight/Obesity
por: Pacifico, Lucia, et al.
Publicado: (2016)

One Year’s Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial
por: Vedtofte, Louise, et al.
Publicado: (2020)

Fibroblast Growth Factors for Nonalcoholic Fatty Liver Disease: Opportunities and Challenges
por: Tian, Haoyu, et al.
Publicado: (2023)

Circulating periostin in relation to insulin resistance and nonalcoholic fatty liver disease among overweight and obese subjects
por: Yang, Zhen, et al.
Publicado: (2016)

Comparison of Body Mass Index and Fat Indices in Predicting the Severity of Nonalcoholic Fatty Liver Disease Among Children Who Are Overweight and Obese
por: Chao, Hsun-Chin, et al.
Publicado: (2021)

Liraglutide Attenuates Nonalcoholic Fatty Liver Disease through Adjusting Lipid Metabolism via SHP1/AMPK Signaling Pathway
por: Yu, Peng, et al.
Publicado: (2019)

Liraglutide on type 2 diabetes mellitus with nonalcoholic fatty liver disease: A systematic review and meta-analysis of 16 RCTs
por: Zhao, Yan, et al.
Publicado: (2023)

Visceral-to-Subcutaneous Abdominal Fat Ratio Is Associated with Nonalcoholic Fatty Liver Disease and Liver Fibrosis
por: Jung, Chan-Hee, et al.
Publicado: (2020)

Combined metabolic activators therapy ameliorates liver fat in nonalcoholic fatty liver disease patients
por: Zeybel, Mujdat, et al.
Publicado: (2021)

Newly Diagnosed Idiopathic Liver Abscess: Colonoscopy Required!
por: Makkar, Priyanka, et al.
Publicado: (2017)

Liver pathology in children with newly diagnosed celiac disease
por: Kwiatek-Średzińska, Kamila Agnieszka, et al.
Publicado: (2019)

ABO blood group and risk of newly diagnosed nonalcoholic fatty liver disease: A case-control study in Han Chinese population
por: Zhong, Guo-Chao, et al.
Publicado: (2019)

Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanism and Application of Metabolomics
por: He, Xuyun, et al.
Publicado: (2016)

Decreased Sclerostin Secretion in Humans and Mice With Nonalcoholic Fatty Liver Disease
por: Zhou, Fangli, et al.
Publicado: (2021)

Nonalcoholic Fatty Liver Disease: Noninvasive Methods of Diagnosing Hepatic Steatosis
por: AlShaalan, Rasha, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_v49en392ag1oh6p2u2v5g83vrc